Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05416333 · ClinicalTrials.gov registry record · Early Phase 1
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
A Early Phase 1 study of Central Centrifugal Cicatricial Alopecia, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05416333: Active Early Phase 1 study of Central Centrifugal Cicatricial Alopecia, sponsored by Wake Forest University Health Sciences.
NCT05416333 is a Early Phase 1 study of Central Centrifugal Cicatricial Alopecia that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05416333, a Early Phase 1 study of Central Centrifugal Cicatricial Alopecia, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.
Primary Outcome
measured by standardized photos and dermatoscope photos
Conditions Studied
Interventions
- DRUG azelaic acid
- OTHER usual medication for CCCA
Study Locations (1)
North Carolina
- Wake Forest University Health Scieces - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What the registry record for NCT05416333 still lists
NCT05416333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Central Centrifugal Cicatricial Alopecia appearing as the primary indexed condition, and to 2 interventions - of which azelaic acid is the first listed.
NCT05416333 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05416333 about?
NCT05416333 is a clinical study titled "Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)". The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hai...
What is the current status of trial NCT05416333?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-12. Estimated completion is 2026-12.
What conditions does trial NCT05416333 study?
This clinical trial studies the following conditions: Central Centrifugal Cicatricial Alopecia.
What interventions are being tested in trial NCT05416333?
The interventions under investigation include: azelaic acid (DRUG), usual medication for CCCA (OTHER).
Who is sponsoring clinical trial NCT05416333?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05416333 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Centrifugal Cicatricial Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05416333's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI